University of Arizona College of Medicine – Tucson

Phoenix Children's Expands Research Team with Scientist Pioneering New Childhood Cancer Treatments

Retrieved on: 
Tuesday, October 17, 2023
Physician, Lung cancer, Pediatric nursing, Doctor of Philosophy, Phoenix Children's Hospital, American Cancer Society, American Cancer Society Cancer Action Network, University of Arizona College of Medicine – Tucson, Cardiology, Neurology, Proton, Pharmacist, Nanoparticle, University, Biostatistics, The Ride to Conquer Cancer, Patient, University of Illinois at Chicago, Nursing, Research, Conquer, Cincinnati Children's Hospital Medical Center, Molecular biology, Medicine, Bangladesh Technical Education Board, Metastasis, Neoplasm, Vinnytsia National Medical University. N. I. Pirogov, Chronic lung disease, Pharmaceutical industry, Dentistry, MD, Cancer

PHOENIX, Oct. 17, 2023 /PRNewswire/ -- Phoenix Children's, one of the nation's fastest-growing pediatric health systems, continues to strengthen its focus on pediatric research with the hire of Tanya Kalin, MD, PhD, a renowned scientist focused on pioneering effective treatments for pediatric cancers with fewer negative side effects for children. Dr. Kalin also serves as vice chair of translational research for the Phoenix Children's Center for Cancer and Blood Disorders, and as a professor of Child Health at the University of Arizona College of Medicine – Phoenix.

Key Points: 
  • Dr. Kalin also serves as vice chair of translational research for the Phoenix Children's Center for Cancer and Blood Disorders , and as a professor of Child Health at the University of Arizona College of Medicine – Phoenix.
  • Dr. Kalin, who assumed her new post in recent weeks, comes to Phoenix Children's from Cincinnati Children's, where she founded and directed her namesake Kalin Research Lab.
  • Two members of her lab also are moving to Phoenix Children's to continue their research with Dr. Kalin.
  • Research underway at Phoenix Children's consists of more than 700 active studies, 640 research investigators and 90 research staff members including research scientists, associates, biostatisticians, pharmacists, nurses, coordinators and assistants.

Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma

Retrieved on: 
Tuesday, October 17, 2023
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Incidence, Cancer, Fast track (FDA), Food, GBM, Glioblastoma, Standard of care, Cell, Central nervous system, University, University of Arizona College of Medicine – Tucson, B cell, Baylor College of Medicine, Survival, Disease, South Texas Medical Center, MD Anderson Cancer Center, Cooper University Hospital, Viral, Neurosurgery, Immunology, Person, Texas Medical Center, Clinical trial, Immune system, Fast Track, Associate, Assistant, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Injection, Baylor University, University of Arizona College of Medicine – Phoenix, Patient, Pharmaceutical industry, Vaccine

Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.

Key Points: 
  • Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.
  • The designation was based on positive preliminary safety and efficacy data from a Phase 1 clinical trial enrolling patients with glioblastoma multiforme (GBM).
  • FDA Fast Track designation is intended to speed development and review of drugs that show early clinical promise in treating severe or life-threatening conditions.
  • This pivotal designation can help propel Diakonos closer to delivering DOC1021 to GBM patients, of which only 7% survive more than five years.

Florida Cancer Specialists & Research Institute Announces Bradley Monk, MD as Medical Director of Late-Phase Clinical Research Program

Retrieved on: 
Tuesday, October 10, 2023
FCS, Investment, Obstetrics, Medicine, Physician, HonorHealth Scottsdale Osborn Medical Center, Real, National Cancer Institute, University of Arizona College of Medicine – Tucson, Standard of care, MD, University, Safety, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Cancer, Medical director, Patient, Gynaecology, Cervical cancer, Sarah Cannon Research Institute, Specialization, Research, Nursing, Pharmaceutical industry

FORT MYERS, Fla., Oct. 10, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that Bradley Monk, MD will join the statewide practice as Medical Director of Late-Phase Research, effective January 1, 2024.

Key Points: 
  • FORT MYERS, Fla., Oct. 10, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that Bradley Monk, MD will join the statewide practice as Medical Director of Late-Phase Research, effective January 1, 2024.
  • Bradley Monk, MD to join FCS as Medical Director of Late-Phase Clinical Research in January 2024.
  • Board-certified in gynecologic oncology and obstetrics and gynecology, Dr. Monk joins FCS with extensive experience in clinical research and the development of clinical research programs in community oncology settings.
  • "The research and innovation coming out of FCS is paving the way for the next generation of medical oncologists and hematologists.

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Retrieved on: 
Wednesday, September 6, 2023
KOL, University, Oregon Health & Science University, Platinum, University of Arizona College of Medicine – Tucson, Doctor of Philosophy, University of California, San Diego, Patient, SUNY Downstate Health Sciences University, FACS, Ovarian cancer, Cancer, Knight Cancer Institute, Safety, Pharmaceutical industry, FACOG, MD

Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET.

Key Points: 
  • Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET.
  • To register for the event, please click here .
  • The event will feature Bradley J. Monk, MD, FACS, FACOG (University of Arizona College of Medicine) and Ramez N. Eskander, MD (University of California San Diego) who will discuss the clinical development opportunity for NXP800 in ovarian cancer, and specifically in patients with platinum resistant, ARID1a-mutated ovarian carcinoma, a patient population that is currently being enrolled into an ongoing Phase 1b clinical trial in which the safety and preliminary efficacy of NXP800 is being investigated, and Gordon Mills, MD, PhD (Knight Cancer Institute, Oregon Health & Science University) who will discuss the clinical development opportunities for NXP900 as the Phase 1a dose escalation study is about to commence.
  • A live question and answer session will follow the formal presentations.

Ramon W. Johnson, M.D., M.B.A, Becomes ABEM President

Retrieved on: 
Monday, July 24, 2023
Ohio State University, HealthPartners, Saint Anne, Denver Health Medical Center, Emergency medicine, University, Pediatrics, ABEM, Doctor, Professional, American Board of Emergency Medicine, Multimedia, University of Arizona College of Medicine – Tucson, Mel, Global Health, American Board of Commissioners for Foreign Missions, Regions Hospital, Banner University Medical Center Tucson, Public health, University of Colorado School of Medicine, Medical director, Patient, Division, Executive Committee, Mission Hospital (Mission Viejo, California), Hospital, S-1 Executive Committee, University of Connecticut School of Medicine, St. Anne's Hospital, Biostatistics, Management, Epidemiology

EAST LANSING, Mich., July 24, 2023 /PRNewswire/ -- Ramon W. Johnson, M.D., M.B.A., is the new President of the American Board of Emergency Medicine (ABEM).

Key Points: 
  • EAST LANSING, Mich., July 24, 2023 /PRNewswire/ -- Ramon W. Johnson, M.D., M.B.A., is the new President of the American Board of Emergency Medicine (ABEM).
  • "It is an incredible honor to represent ABEM as a community physician.
  • Continuing to set the highest standards for knowledge assessment and professionalism for all emergency physicians will benefit our patients and the specialty."
  • Dr. Kendall is Professor of Emergency Medicine and Vice Chair of Education at the University of Colorado School of Medicine.

Premier Anesthesia Announces the Appointment of Two Regional Medical Directors

Retrieved on: 
Thursday, July 20, 2023
Communication, University, University of Arizona College of Medicine – Tucson, MHSA, MBA, FASA, American Society of Anesthesiologists, University of Alabama at Birmingham School of Medicine, National Association Medical Staff Services, DO, Business administration, Hospital, MD, JD, Knowledge, Health, Fellow, Society, Health information management, Anesthesiology, Medical device, Management, Nursing, Kadlec, Anesthesia

ALPHARETTA, Ga., July 20, 2023 /PRNewswire/ -- Premier Anesthesia, a national leader and specialist in anesthesia practice management, has announced the promotions of Miguel Cervantes III, MD, MBA, FASA, and Anthony Dominic, DO, MHSA to the positions of regional medical directors.

Key Points: 
  • Premier Anesthesia announced the promotions of Miguel Cervantes and Anthony Dominic to Regional Medical Directors.
  • Dr. Cervantes has been affiliated with Premier Anesthesia since 2005 and has worked at multiple facilities operated by Premier.
  • Currently based in Richland, Washington, Dr. Cervantes serves as Kadlec Regional Medical Center's anesthesia medical director and is a member of the medical board for three ambulatory surgery centers.
  • In addition to his role as a regional anesthesia medical director for Premier Anesthesia, he is a medical director of anesthesia for Mount Carmel Grove City.

New Research Shows Sleep Reset Is First & Only Digital Sleep Solution Clinically Proven to Increase Total Sleep Time by Over One Hour for Short Sleepers

Retrieved on: 
Tuesday, June 6, 2023
TST, University, Zolpidem, Sagrada Reset, Cognitive behavioral therapy, Eszopiclone, Melatonin, Research, University of Arizona College of Medicine – Tucson, Associate, University of Arizona College of Pharmacy, Dementia, Risk, SAN, Trazodone, Psychiatry, Knowledge, Ageing, Cognitive behavioral therapy for insomnia, Benadryl, Female, Reset, Tutoring, Pharmaceutical industry, Sleep, Insomnia

The University of Arizona's Sleep and Health Research Program led the study which shows Sleep Reset's ability to increase sleep time, addressing a significant concern for many healthcare professionals.

Key Points: 
  • The University of Arizona's Sleep and Health Research Program led the study which shows Sleep Reset's ability to increase sleep time, addressing a significant concern for many healthcare professionals.
  • "Remarkably, data from Sleep Reset reveals that this program has the potential to significantly extend the duration of their sleep.
  • Many popular sleep solutions like Trazadone, Benadryl and Melatonin don't even have the clinical evidence to increase total sleep time much at all.
  • Ambien and Lunesta are known to increase sleep time by around 30 minutes, but that's much less than what we've seen from Sleep Reset.

The Inner Circle Acknowledges, Stephanie E. Gore as a Top Pinnacle Professional for her contributions to the Obstetrics and Gynecology Fields

Retrieved on: 
Friday, May 26, 2023
AAGL, Bachelor of Science in Nursing, University, Obstetrics, American Board of Obstetrics and Gynecology, National Medical Association, Professional, Multimedia, University of Arizona College of Medicine – Tucson, New York Medical College, Inner circle, American Medical Association, Puberty, American Board of Commissioners for Foreign Missions, Public health, Patient, Physician, University of Arizona, Ulster County, New York, Knowledge, Northern Westchester Hospital, American College, Health, Fellow, Family, ABOG, Female, Nursing, Gynaecology

BRONX, N.Y., May 26, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Stephanie E. Gore is acknowledged as a Top Pinnacle Professional for her contributions to the Obstetrics and Gynecology Fields.

Key Points: 
  • BRONX, N.Y., May 26, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Stephanie E. Gore is acknowledged as a Top Pinnacle Professional for her contributions to the Obstetrics and Gynecology Fields.
  • Dr. Gore began her educational journey at The University of Arizona where she earned a Bachelor of Science degree.
  • Dr. Gore delivers babies and has a comprehensive gynecologic practice focusing on robotic laparoscopic surgeries and traditional surgical procedures.
  • A testament to her knowledge and skill, Dr. Gore is board-certification in obstetrics and gynecology through the American Board of Obstetrics and Gynecology (ABOG).

Phoenix Children's Research Institute at the University of Arizona College of Medicine - Phoenix Created to Bolster Pediatric Cures, Treatments

Retrieved on: 
Thursday, May 25, 2023
Workforce, Psychology, Patient-Centered Outcomes Research Institute, Partnership, University, Therapy, Phoenix Children's Hospital, Medicine, COVID-19, Health, Myocarditis, Research, Inflammation, History, Multisystem inflammatory syndrome, Cerebral palsy, Doctor of Philosophy, MS, University of Arizona College of Medicine – Tucson, Barrow Neurological Institute, Incidence, Regeneration, JAMA Network Open, Patient, Fracture, Risk, Arizona State University, PCORI, Reading, Language, Diagnosis, Research institute, Worldwide Angel, Trial of the century, Dyslexia, Environment, NIH, Safety, Pharmaceutical industry, Nursing, Dentistry, Child, MD

PHOENIX, May 25, 2023 /PRNewswire/ -- Phoenix Children's, one of the nation's fastest-growing pediatric healthcare systems, and the University of Arizona College of Medicine – Phoenix, today announced the creation of The Phoenix Children's Research Institute at the University of Arizona College of Medicine – Phoenix, a collaboration that will allow clinicians to accelerate research efforts.

Key Points: 
  • PHOENIX, May 25, 2023 /PRNewswire/ -- Phoenix Children's, one of the nation's fastest-growing pediatric healthcare systems, and the University of Arizona College of Medicine – Phoenix, today announced the creation of The Phoenix Children's Research Institute at the University of Arizona College of Medicine – Phoenix, a collaboration that will allow clinicians to accelerate research efforts.
  • "This institute formalizes a longstanding research collaboration between Phoenix Children's and the University of Arizona College of Medicine – Phoenix," said Robert L. Meyer, President and CEO of Phoenix Children's.
  • Vlad Kalinichenko, MD, PhD will serve as director for the Phoenix Children's Research Institute at the University of Arizona College of Medicine – Phoenix, and professor of Child Health with tenure.
  • He will work alongside pediatric cancer research luminary Stewart Goldman, MD , senior vice president of research for Phoenix Children's and chair of the Department of Child Health at the University of Arizona College of Medicine – Phoenix.

Babson Diagnostics Welcomes New Clinical Advisor, Andrew Carroll, M.D.

Retrieved on: 
Monday, April 10, 2023
Technology, Biotechnology, Alternative Medicine, Health, Other Health, Pharmaceutical, Other Science, Other Technology, Practice Management, Research, Medical Devices, General Health, Health Technology, Science, University, Diagnosis, Carroll, American Academy, Human, Multimedia, University of Arizona College of Medicine – Tucson, Babson, Patient, Collection, Physician, Blood, American Academy of Family Physicians, Pharmaceutical industry, Medical device

Andrew Carroll, M.D., a family physician and clinical assistant professor at the University of Arizona College of Medicine, will provide advice and counsel about clinical best practices and review validation data and reports.

Key Points: 
  • Andrew Carroll, M.D., a family physician and clinical assistant professor at the University of Arizona College of Medicine, will provide advice and counsel about clinical best practices and review validation data and reports.
  • Dr. Carroll will join Babson at industry events, trade shows, and clinical meetings.
  • He will also assist in assembling a clinical advisory board to support the company in embedding clinical best practices.
  • “I love collaborating with innovative companies like Babson who are focused on making health easier for all.”